from MNTarthritis - 04 Apr 11
TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces today the approval by AFSSAPS, the French regulatory agency, of its application to carry out a phase I/II clinical trial of its second product candidate, TX-RAD...